| Lightcalls.com |
|
|
![]() |
How many times have you portented ...How many times have you portented where to refer your clients when asked about growing capital for small and medium-sized enterprises (SMEs)? for aye get frustrated, thinking that no financial institution (in spite of all their advertising to the contrary) is really in the business of financing small business? Well, things are beginning to change. Capital markets are becoming increasingly sophisticated, and many more financial tools are now available to entrepreneurs Finding the right source An optimal capital arrangement must be consistent with a company's objectives for sprouting flexibility, and exit strategy. At the same time, entrepreneur must be realistic. They must recognize that, in large part, the greatest in quantity appropriate sources of capital are bridleed by their firm's stage of development Because financing indigences evolve with growth, a capital texture that fits at one stage may not fit at another. in this way here's an overview of the appropriate sources at three different stages in a company's evolution: Start-up Approximately 5% of Canadian SME are start-ups. These seed-stage companies typically lack incomes are not profitable, and have not many balance sheet assets to speak of which means they're unable to demonstrate the cash come required to service debt outcomes and lack the acceptable collateral to guarantee as security. As a proceed bank financing is difficult to obtain for companies at this stage. Given the risk profile associated with start-ups, equity investment and rule support are the most appropriate sources of financing. Seed-stage equity investment can be obtained from friends and family (affectionately referr to as "love money") angel investors, and equity capitals specializing in seed investments. so funds include the Canadian Science and Technology pullulation Fund, the Western Technology Se permanent fund and Yaletown Venture Partners. Publicly traded capital collection of standing water companies (CPCs) are another equity option for se stage jeopardys And in terms of management support, the Science Council of BC the National Research Council, Western Economic Diversification, and various tax credit incentive programs giveed by the CCRA are among the best sources. Early growth Usually early-stage expansion companies have commercialized a harvest and are enjoying modest incomes although profit is still unlikely (due to investments in marketing, a ramping up of staff, and other initiatives) and the balance sheet remains weak as the terminate of losses incurred during the start-up phase. In this stage of progressive growth love money and angel investors remain relevant. Equity can also be obtained from adventure capital (VC) funds. Surprisingly, while risk capital-especially in the form of equity-is a critical component part in financing, particularly for growing SME solitary 2.4% of small businesses demanded such investment in 2000. In the BC words immediately preceding [i]or[/i] following the main VC players are Growthworks, the Business increase Bank's Venture Capital group, Banyan Capital Partners, Discovery Capital, Greenstone hap Partners, Ventures West, and MD Capital. Certain alternative sources of financing may also be appropriate at this stage. For companies that have well adapted quality receivables but need to shorten their working capital periods by collecting them faster, factoring may be another option (Pyx Financial assemblage First Vancouver Finance, Liquid Capital). And equipment leasing and/or asset-backed financing may also be suitable; case in point: 9% of SME made a solicit for a lease in 2000 with an overall approval rating of almost 98% Later growth Later-stage produce companies are characterized by substantial and growing incomes profitability, and positive cash roll on although large investments in marketing, capital equipment, and other items are still required. At this stage of unravelling balance sheets are strengthening. Debt becomes a viable option for many companies at this stage, and reach [i]or[/i] attain any place [i]or[/i] points in two main forms: * Senior debt Provided primarily by the agency of the chartered banks and credit unions, senior offence is available to companies that have a track record of profitability and are able to earnest good quality security. It note carefullys to be aggressively priced and highly competitive. In 2000 23% of SME made a entreaty for debt, with an overall approval rate of 82% mostly requests (66%) were made to chartered banks, nevertheless credit unions and caisses populaires had the highest overall approval rate at 88% * Subordinated debt Like senior offence subordinated debt (or "sub" debt) is available to companies that can demonstrate cash grow and a clear ability to make loan payments. The distinguishing feature between subordinated and senior trespass lies in the security requirements. Sometimes referr to as "quasi-equity," sub sin is designed for companies that are profitable and cash stream positive, but do not have sufficient (or the right kind of) security to guarantee These can include technology companies and service businesses (including, in a certain number of cases, advanced manufacturing). Local sources of quasi-equity for small and medium-sized businesses include VanCity Capital, RoyNat, the Business progressive growth Bank's sub debt group, and the Bank of Montreal Capital Corporation. |
![]() |
Other Articles
-Morphotek will collaborat...-Eksigent Technologies nam... -The benefits of outsourci... -Sartorius Corporation ... -In our previous column, w... -Efoora appointed Michael ... -Affymax appointed Anne-Ma... -Traditionally, continuous... -New Brunswick Scientific ... -The German-American firm ... -Don G. Burstyn, formerly ... -American patients are mor... -Summary Prior to va... -BioPharm Editorial Adviso... -Australia agreed to spend... -The Biotechnology Industr... -Ambion, The RNA Company i... -Therapies based on living... -A recent survey found tha... -ViroLogic will acquire Ac... -Cardinal Health named Joh... -One of the greatest chall... -As the president of a sma... -Sweden-based Biovitrum wi... -Nanogen appointed David L... -The Experion Process Know... -Although biomedical resea... -The Supreme Court of Cana... -Netherlands-based DSM Bio... -David A. Smoller joined S... -A few months ago, I wrote... -Panacos Pharmaceuticals w... -Karen K. Vaccaro will res... -Acceleron Pharma appointe... -Two quarterly meetings of... -Illinois-based Abbot Labo... -FKI Logistics announced t... -The following corrections... -It its widest definition,... -UK-based Xcellsyz will li... -Andrew P. Aromando joined... -Invitrogen's comprehensiv... -Last month, we described ... -The Swiss life sciences c... -Protein Design Labs (PDL)... -Model It HNMR, the newest... -Tech transfer, like chang... -QLT and Atrix Laboratorie... -Dendreon announced Christ... -Baxter Pharmaceutical Sol... -The biopharmaceutical ind... -GlaxoSmithKline announced... -Montreal-based Caprion Ph... -Xenova Group recently ann... -Cole-Parmer's new 192-pag... -Over the last decade ther... -Benchmark your facility p... -As biotechnology organiza... -Frederick D. Sancillo, fo... -Insmed acquired a recombi... -Baxter Pharmaceutical Sol... -Model It HNMR, the newest... -DA's regulation 21 CFR Pa... -Robert P. Ryan joined Ath... -A new report from Busines... -Biotest offers a complete... -Swagelok offers a brochur... -Partnering is a global ph... -Human Genome Sciences CEO... -Shorten the process devel... -The licensure of biotechn... -Rodger Currie joined Amge... -The GEA Filtration Model ... -A multi-channel chemistry... -From June 6-9, San Franci... -Skanska USA Building Inc.... -New Brunswick Scientific'... -AVI BioPharma appointed P... -Ambion, The RNA Company, ... -"If you want to be a... -Xcellerex appointed Susan... -Researchers identified th... -Cool Spring Business Park... -In October 2003, Shenzhen... -Laureate Pharma appointed... -After a 6-5 vote by Calif... -QSourcing, a service of Q... -The recent discovery of &... -Affymax added Douglas L. ... -USDA recently approved tw... -BioPharm International is... -Serologicals has released... -This document by Shenzhen... -Robert Bronstein joined A... -Gloucester Gains Fujisawa... -With more than 30 years o... -Pall's SUPRAdisc II depth... -In today's competitive ma... -Protein Design Labs repor... -Charles A. Rice will repl... -AstraZeneca's Faslodex (f... |
| . |